 Home </wps/find/homepage.cws_home> | Site map
</wps/find/sitemap.cws_home/sitemap> | Elsevier websites
</wps/find/elsevierwebsites.cws_home/elsevierwebsites> | Alerts
</wps/find/home_content.cws_home/alertingservices>
	Elsevier 		

	Product information search 	
	Search all Elsevier sites 	
Search <javascript:submitSearchForm(document.forms['searchForm'])> 	
Advanced Product Search
</wps/find/advproductsearch.cws_home?action=product_search&search=no>

	

Go to Elsevier home page </wps/find/homepage.cws_home>

	
	Products
</wps/find/subject_area_browse.cws_home/?sh1State=-null-SAR-SAA-SAC-SAD-SAF-SA1-SAI-SAJ-SAK-SAQ-SAP-SAB-SAE-SAL-SAN-SAO-SAG-SAH-SAM&sh2State=&allParents=y&showAll=y>
	

	Gene
</wps/find/journaldescription.cws_home/506033/authorinstructions?navopenmenu=-2>
	

	Journal information

	Product description
</wps/find/journaldescription.cws_home/506033/description#description> 	

	Editorial board
</wps/find/journaleditorialboard.cws_home/506033/editorialboard#editorialboard>
	

	Audience </wps/find/journalaudience.cws_home/506033/description#audience> 	

	Abstracting/indexing
</wps/find/journalabstracting.cws_home/506033/abstracting#abstracting> 	

	Special issues and supplements
</wps/find/journalspecialissues.cws_home/506033/specialissues#specialissues>
	

	Subscription information

	Bibliographic and ordering information
</wps/find/journalbibliographicinfo.cws_home/506033/description#bibliographicinfo>
	

	Conditions of sale
</wps/find/journalconditionsofsale.cws_home/506033/conditionsofsale#conditionsofsale>
	

	Dispatch dates
</wps/find/journaldispatchdates.cws_home/506033/dispatchdates#dispatchdates>
	

	Journal-related information

	Contact the publisher
</wps/find/journalcontactpublisher.cws_home/506033/contactpublisher#contactpublisher>
	

	Impact factor
</wps/find/journalimpactfactors.cws_home/506033/description#impactfactors> 	

	Most downloaded articles
<javascript:openWindow("http://top25.sciencedirect.com/?journal_id=03781119","topdownload")>
	

	Other journals in same subject area
</wps/find/products_in_subject_and_group.cws_home/506033> 	

	Related publications
</wps/find/journalrelatedpublications.cws_home/506033/relatedpublications#relatedpublications>
	

	Support & contact </wps/find/supportfaq.cws_home/overview> 	

	About Elsevier </wps/find/intro.cws_home/ataglance> 	

	Select your view
</wps/find/journaldescription.cws_home/506033/authorinstructions?navopenmenu=4>
	

	

			
	
	GENE	
		
	
An international journal on genes, genomes and evolution

*Guide for Authors*

*Before preparing a paper for submission to /Gene/,* the author(s)
should carefully read these instructions, and / Gene's/ List of
Abbreviations </inca/publications/misc/geneabbs.pdf>, thus avoiding
needless delays during the editorial process. Papers should be carefully
prepared in/Gene's/ style. When a paper is submitted to /Gene,/ the
corresponding author is responsible for all authors having seen and
approved the original paper and, eventually, the proofs.

The paper should be accompanied by a letter of transmittal, in which the
authors are invited to suggest the names of two editorial board member
who could handle the manuscript as Handling Editors, and to specify the
names of five or more potential referees (including complete addresses,
phone and fax numbers, e-mail addresses and areas of expertise). In
order to ensure a maximum of objectivity, the names of scientists the
authors do not wish to be consulted in the reviewing process can also be
provided, as well as any other special requests.

/Gene/ requires all new nucleotide and amino acid sequences to be
deposited. Obtain and include an accession number with all sequences.
The most convenient method for submitting sequence data is by World Wide
Web:

EMBL <http://www.ebi.ac.uk/embl/Submission/webin.html>
GenBank <http://www.ncbi.nlm.nih.gov/BankIt/>
DDBJ <http://sakura.ddbj.nig.ac.jp/>

Alternatively, the stand-alone submission tool "Sequin" is available
from the EBI <http://www3.ebi.ac.uk/Services/Sequin> and from NCBI <
http://www.ncbi.nlm.nih.gov/Sequin/>

If requested the database will withhold release of data until publication.

If references are quoted as 'In press', the relevant manuscript(s)
should also be attached. Should authors be requested by the Editor to
modify the text prior to publication, the revised version should be
submitted within 2 months. After this period, the manuscript will be
dealt with as a new one.

*SPEED OF PEER REVIEW*

All possible effort will be made by the Editors in order to obtain
referees' comments rapidly. In principle, the authors will be informed
of a decision within 6 weeks.

*TYPES OF SUBMITTED PAPER*

1. *Regular Papers:* Not exceeding a total of 25 double-spaced, font
size 12 typewritten pages, including references, tables, figures and
their legends. The paper should be divided into: *Abstract,
Introduction, Materials and Methods, Results, Discussion.* The last two
sections may be combined. Preliminary results or incompletely documented
data will, however, not be considered for publication.

2. *Reviews* or *Mini-reviews:* will generally be solicited by the
Editors of the journal. However, prospective authors interested in
contributing such a paper are invited to contact the Editor-in-Chief in
advance.

*DETAILED INSTRUCTIONS FOR PREPARING PAPERS*

Papers should be in perfect English, conform to *Gene's* style, be
typed/printed out entirely double-spaced and carefully proofread by all
co-authors. Sections (but not the Abstract) should be numbered 1.1, 1.2,
etc. In the text or legends, always refer to the specific section of the
paper, "see section 1.1, or 3.5..." (do not just refer to "the text").
Number all pages.

*TITLE PAGE* (page No. 1) must be prepared in this order: (a) a brief
descriptive title (lower-case); (b) 4--6 key words (only words not
already in the title); (c) the name(s) of the author(s) (lower-case;
circle complicated or multiple family names); (d) affiliation(s): list
the name of the institute, university, department, city, country
(underline or italicize); if there is more than one affiliation, use
superscript letters directly after the name, to refer to each
affiliation; (e) mark the corresponding author with an asterisk and
place the /Address for Correspondence/ at the bottom of the page
(including full address, phone and fax numbers and e-mail address if
there is one); (f) separate footnotes with the present affiliations of
author(s) who have moved to a different address; (g) abbreviations:
consult /Gene's/ List of Abbreviations and the pertinent literature for
accepted abbreviations, especially for genes and proteins; list all
those used, even if already in /Gene's/ list (create new abbreviations
if necessary). Be meticulous with symbols. For proteins, use Roman
letters with at least the first letter capitalized (e.g., Hprt, HPRT or
βGal; for genes (or DNA) use italicized letters (e.g., /lacZ, hprt,
HPRT/ or /cat/ gene, not HPRTor CAT gene). Consult the nomenclature (or
usage) for the particular organism concerned to use (or create) proper
gene/protein abbreviations.

The *ABSTRACT* (on a separate page) should be concise, describing the
purpose and results of the study, and the final specific conclusions.
Explain any abbreviations when used for the first time. For references
in the Abstract give the concise source reference (e.g., Stamm et al.,
Gene 2005; 344:1-20).

*INTRODUCTION* must be short and must mainly specify the background and
aims of the work (not another Abstract).

*MATERIALS AND METHODS* should contain all the details necessary to
repeat the experimental procedure. Avoid redescribing methods already
published; only relevant modifications should be included in the text.
All pertinent technical details should be specified and be detailed
enough to permit repetition of the experiments. Please add to legends
(for figures) or footnotes (for tables) details such as [temp.,time(s),
voltage, concentrations, type and % of gel, markers,sizes (bp,kb,kDa),
etc.], but outline methods themselves in the main text.

*RESULTS and DISCUSSION* sections should refer to the data shown in the
figures and tables, and briefly discuss their significance. Divide these
sections into numbered subsections with short subtitles (lower-case,
Roman, not underlined). Where the Results section is combined with the
Discussion section, the last subsection, subtitled Conclusions, should
be short and be divided into points.

*REFERENCES* should be assembled alphabetically and typed/printed
double-spaced. They should be referred to by name and year (Harvard
System). More than one citation from the same author(s)and year must be
identified by the letters, a, b, c, etc., placed after the year of
publication. In the text, when referring to a paper by more than two
authors, only the name of the first author should be given, followed by
a non-italicized 'et al.'. When referring to a personal communication or
unpublished paper, all initials and name(s) of all author(s) should be
cited, and written permission from these authors should be submitted to
the Editor. Literature references must be in accord with a recent /Gene/
issue. Journal titles should be abbreviated according to the 'List of
Serials Indexed for Online Users' which can be found on External link
http://www.nlm.nih.gov For reviews with a large number of references,
employ the system used in Gene 1991; 100: 13-26.

*TABLES* should be numbered 1, 2, 3, etc., and, at the top, bear a short
descriptive title. Detailed footnote(s) identified by superscript,
a,b,c...., usually one for each major column, should be presented
double-spaced under the table.

*FIGURES* should be numbered 1, 2, 3, etc., and line drawings (including
graphs) should be prepared as laser-quality computer printouts. Send
original printouts, not photographs. Only if a laser-qualityprinter is
not available (dot matrix printers are unsatisfactory)should you present
professionally drawn figures in black ink on white paper. Always use
large and bold lettering and heavy smoothlines to permit photographic
reduction. Ensure that all symbols in the figure are large and match the
explanations in the legend. Sequence figures should be either 60
nucleotides (or amino acids)in width (to fit into a single printed
column), or 120--150 nt. As a rule no more than a single page is allowed
for sequence figures. Add bp, nt, kb or kDa symbols above the numerals
in marker lanes. Legends should be typed/printed double-spaced, on pages
separate from the figures themselves. The maximum size of figures is A4:
present larger figures on two or more sheets.

*Colour illustrations* in the print version are reproduced at the
author's expense. The publisher will provide the author with a cost
estimate upon receipt of the accepted paper. Colour illustrations in the
online version are always at no cost to the authors. In review articles,
colour illustrations will be reproduced free of charge if essential for
the presentation of results. This will be at the discretion of the
Editor-in-Chief.

*Language Polishing.* Authors who require information about language
editing and copyediting services pre- and post-submission please visit
External link
http://www.elsevier.com/wps/find/authorshome.authors/languagepolishing
or contact authorsupport@elsevier.com <mailto:uthorsupport@elsevier.com>
for more information. Please note Elsevier neither endorses nor takes
responsibility for any products, goods or services offered by outside
vendors through our services or in any advertising. For more information
please refer to our Terms & Conditions External link
http://www.elsevier.com/wps/find/termsandconditions.cws_home/termsconditions


*Articles in Special Issues*: Please ensure that the words /this issue/
are added (in the list and text) to any references to other articles in
this Special Issue.

*Instructions for authors regarding GenBank/DNA sequence linking*

*DNA sequences and GenBank Accession numbers*
Many Elsevier journals cite 'gene accession numbers' in their running
text and footnotes. Gene accession numbers refer to genes or DNA
sequences about which further information can be found in the databases
at the National Center for Biotechnical Information (NCBI) at the
National Library of Medicine. Elsevier authors wishing to enable other
scientists to use the accession numbers cited in their papers via links
to these sources, should type this information in the following manner:

/For each and every/accession number cited in an article, authors should
type the accession number in * _bold, underlined text._ * Letters in the
accession number should always be capitalized. (See Example 1 below).
This combination of letters and format will enable Elsevier's
typesetters to recognize the relevant texts as accession numbers and add
the required link to GenBank's sequences.

*Example 1:* '(GenBank accession nos. * _AI631510,_ * * _AI631511,_ * *
_AI632198,_ * and * _BF223228),_ * a B-cell tumor from a chronic
lymphatic leukemia (GenBank accession no. * _BE675048),_ * and a T-cell
lymphoma (GeneBank accession no. * _AA361117)_ *'.

Authors are encouraged to check accession numbers very carefully. *An
error in a letter or number can result in a dead link.*

In the final version of the * /printed/ * *article,* the accession
number text will not appear bold or underlined (see Example 2 below).

*Example 2:* 'GenBank accession nos. AI631510, AI631511, AI632198, and
BF223228), a B-cell tumor from a chronic lymphatic leukemia (GenBank
accessionno.BE675048), and a T-cell lymphoma (GenBank accession no.
AA361117)'.

In the final version of the * /electronic/ * *copy,* the accession
number text will be linked to the appropriate source in the NCBI
databases enabling readers to go directly to that source from the
article (see Example 3 below).

*Example 3:* 'GeneBank accession nos. _AI631510,_ _AI631511,_
_AI632198,_ and _BF223228),_ a B-cell tumor from a chronic lymphatic
leukemia (GenBank accession no. _BE67048),_ and a T-cell lymphoma
(GenBank accession no. _AA361117)')_.

*SUPPLEMENTARY DATA*

Elsevier accepts electronic supplementary material to support and
enhance scientific research. Supplementary files offer the author
additional possibilities to publish supporting applications, movies,
animation sequences, high-resolution images, background datasets, sound
clips and more. Supplementary files supplied will be published online
alongside the electronic version of the article in Elsevier web
products, including ScienceDirect <http://www.sciencedirect.com>.
Authors should submit the material in electronic format together with
the article and supply a concise and descriptive caption for each file.
For more detailed instructions please visit External link
http://www.elsevier.com/authors.

*PROOFREADING*

One set of proofs, as an e-mail PDF, will be sent to the corresponding
author as given on the title page of the manuscript. Only typesetter's
errors may be corrected; no changes in, or additions to, the edited
manuscript will be allowed. Elsevier will do everything possible to get
your article corrected and published as quickly and accurately as
possible. Therefore, it is important to ensure that all of your
corrections are sent back to us in one communication. Subsequent
corrections are not possible, so please ensure your first sending is
complete.

*NO PAGE CHARGES*

There will be no page charges.

*OFFPRINTS*

Twenty-five offprints of each paper will be provided free of charge.
Additional copies may be ordered at the prices shown on the Price List
which will be sent by the publisher to the author together with the
offprint order form upon receipt of the accepted manuscript.

*US National Institutes of Health (NIH) voluntary posting (" Public
Access") policy*

Elsevier facilitates author response to the NIH voluntary posting
request (referred to as the NIH "Public Access Policy"; (see
http://www.nih.gov/about/publicaccess/index.htm) by posting the
peer-reviewed author's manuscript directly to PubMed Central on request
from the author, 12 months after formal publication. Upon notification
from Elsevier of acceptance, we will ask you to confirm via e-mail (by
e-mailing us at NIHauthorrequest@elsevier.com
<mailto:NIHauthorrequest@elsevier.com>) that your work has received NIH
funding and that you intend to respond to the NIH policy request, along
with your NIH award number to facilitate processing. Upon such
confirmation, Elsevier will submit to PubMed Central on your behalf a
version of your manuscript that will include peer-review comments, for
posting 12 months after formal publication. This will ensure that you
will have responded fully to the NIH request policy. There will be no
need for you to post your manuscript directly with PubMed Central, and
any such posting is prohibited.

*ONLINE MANUSCRIPT TRACKING*

Authors can keep track on the progress of their manuscripts, and set up
e-mail alerts informing them of changes to their manuscript's status, by
using the "Track a Paper" feature at External link
http://www.elsevier.com/trackarticle.

	
		

		

		
	
Printer-friendly version <javascript:openPrinterFriendlyPage()>
  Printer-friendly version <javascript:openPrinterFriendlyPage()>

	

		

		
	
	
 Home </wps/find/homepage.cws_home> | Site map
</wps/find/sitemap.cws_home/sitemap> | Privacy policy
</wps/find/privacypolicy.cws_home/privacypolicy> | Terms and Conditions
</wps/find/termsconditions.cws_home/termsconditions> | Feedback
</wps/find/feedbackform.cws_home> | A Reed Elsevier
<http://www.reed-elsevier.com> company 	
 Copyright © 2007 Elsevier B.V. </wps/find/homepage.cws_home> All rights
reserved.

	

